Evidence map›Paper›PMID 34599873›Full record

ArticleCell chemical biology2022

Identification of cell wall synthesis inhibitors active against Mycobacterium tuberculosis by competitive activity-based protein profiling.

Michael Li, Hiren V Patel, Armand B Cognetta, Trever C Smith, Ivy Mallick, Jean-François Cavalier, Mary L Previti, Stéphane Canaan, Bree B Aldridge, Benjamin F Cravatt and 1 more

Open access · hybridAbstract readComment
In one paragraph

Article in Cell chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Chemical biology tools to probe bacterial glycans.Current opinion in chemical biology · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Target Identification in Anti-Tuberculosis Drug Discovery.International journal of molecular sciences · 2023
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Michael LiDepartment of Pharmacological Sciences and Immunology Stony Brook University, Stony Brook, NY 11790, USA.
Hiren V PatelDepartment of Microbiology and Immunology Stony Brook University, Stony Brook, NY 11790, USA.
Armand B CognettaDepartment of Chemistry, Scripps Research Institute, La Jolla, CA 92037, USA.
Trever C SmithDepartment of Molecular Biology and Microbiology, Tufts University, Boston, MA 02111, USA.
Ivy MallickAix-Marseille Université, CNRS, LISM, IMM FR3479, 13402 Marseille, France.
Jean-François CavalierAix-Marseille Université, CNRS, LISM, IMM FR3479, 13402 Marseille, France.
Mary L PrevitiDepartment of Pharmacological Sciences and Immunology Stony Brook University, Stony Brook, NY 11790, USA.
Stéphane CanaanAix-Marseille Université, CNRS, LISM, IMM FR3479, 13402 Marseille, France.
Bree B AldridgeDepartment of Molecular Biology and Microbiology, Tufts University, Boston, MA 02111, USA.
Benjamin F CravattDepartment of Chemistry, Scripps Research Institute, La Jolla, CA 92037, USA.
Jessica C SeeligerDepartment of Pharmacological Sciences and Immunology Stony Brook University, Stony Brook, NY 11790, USA. Electronic address: jessica.seeliger@stonybrook.edu.
Centre National de la Recherche Scientifique · FRStony Brook University · USScripps Research Institute · USTufts University · USStony Brook Medicine · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008444 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI FROHMAN, MICHAEL A. · 1992 to 2024
$12.6M
Infectious Disease Training-Pathogenesis/Host ResponseT32AI007329 · NIAID · TUFTS MEDICAL CENTER · PI HU, LINDEN T · 1988 to 2018
$4.1M
Quantitative Design of Multi-drug Regiments for TuberculosisDP2LM011952 · NLM · TUFTS UNIVERSITY BOSTON · PI ALDRIDGE, BREE BEARDSLEY · 2013 to 2018
$2.9M
Chemical Biology Training InterfaceT32GM136572 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI ELIZABETH M BOON, Jessica Chuang Seeliger · 2020 to 2026
$2.9M
Single-cell factors of tuberculosis drug tolerance during adaptation to environmental stressorsR01AI143611 · NIAID · TUFTS UNIVERSITY BOSTON · PI ALDRIDGE, BREE BEARDSLEY · 2020 to 2023
$2.8M
Untangling the Inner Workings of the Mycobacterial Cell EnvelopeR35GM128552 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI SEELIGER, JESSICA CHUANG · 2018 to 2022
$2.1M
SBU Chemistry-Biology Interface Training ProgramT32GM092714 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI SAMPSON, NICOLE S, TONGE, PETER J · 2010 to 2019
$1.7M
Identification and inhibition of hydrolases in Mycobacterium tuberculosisF30AI112203 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI PATEL, HIREN VIJAY · 2015 to 2016
$56k
NIAID NIH HHS F30 AI112203NIAID NIH HHS R01 AI143611NIAID NIH HHS T32 AI007329NIGMS NIH HHS R35 GM128552NIGMS NIH HHS T32 GM008444NIGMS NIH HHS T32 GM092714NIGMS NIH HHS T32 GM136572NLM NIH HHS DP2 LM011952
6 · The paper itself

Abstract

The identification and validation of a small molecule's targets is a major bottleneck in the discovery process for tuberculosis antibiotics. Activity-based protein profiling (ABPP) is an efficient tool for determining a small molecule's targets within complex proteomes. However, how target inhibition relates to biological activity is often left unexplored. Here, we study the effects of 1,2,3-triazole ureas on Mycobacterium tuberculosis (Mtb). After screening ∼200 compounds, we focus on 4 compounds that form a structure-activity series. The compound with negligible activity reveals targets, the inhibition of which is functionally less relevant for Mtb growth and viability, an aspect not addressed in other ABPP studies. Biochemistry, computational docking, and morphological analysis confirms that active compounds preferentially inhibit serine hydrolases with cell wall and lipid metabolism functions and that disruption of the cell wall underlies biological activity. Our findings show that ABPP identifies the targets most likely relevant to a compound's antibacterial activity.

Indexed as

Mycobacterium tuberculosisTuberculosisAntitubercular AgentsCell WallHumansProteomeAntitubercular AgentsProteomeactivity-based probechemoproteomicsinhibitorMycobacteriumserine hydrolasetriazole ureatuberculosis

Identifiers

PMID34599873
PMCPMC8964833
OpenAlexW3202861230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.